Metformin's Murky Impact: A Primate Study Sheds Light on Pregnancy Risks

A new study warns that metformin, used to manage diabetes during pregnancy, could restrict fetal growth. Research involving primates showed that the drug crosses the placenta and accumulates in the fetus, potentially affecting kidney development and reducing body weight.

A recent study raises alarms about the widespread use of metformin in pregnant women, suggesting that the anti-diabetes medication could impede fetal growth. Conducted by researchers at Baylor College of Medicine, the study found that metformin can cross the placenta and build up in fetal organs including the kidneys and liver.

The research involved primate experiments, where pregnant rhesus monkeys were administered metformin. Subsequent analysis showed that the drug accumulated significantly in fetal tissues, leading to growth restrictions. Remarkably, it was found that fetal levels of metformin matched those seen in the mother's urine, prompting concerns over the drug's long-term impact on child development.

No dietary influence on metformin levels was observed, as animals on both regular and high-fat diets showed similar drug concentration levels. While the study's limited scope calls for further exploration, the findings signal a need for cautious administration of metformin during pregnancy.

(With inputs from agencies.)